Trials / Terminated
TerminatedNCT01295697
Study of EZN-2208 Pediatric Patients With Solid Tumors
A Phase 1/2 Study of EZN-2208 in Children, Adolescents, and Young Adults With Relapsed or Refractory Solid Tumors
- Status
- Terminated
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Enzon Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 1 Year – 21 Years
- Healthy volunteers
- Not accepted
Summary
The goal of this clinical research study is to find the highest tolerable dose of EZN-2208 that can be given to pediatric patients with Relapsed or Refractory Solid Tumors. The safety of the study drug and its effect on the disease will also be studied.
Detailed description
Pharmacokinetic (PK) testing of EZN-2208, will be performed for patients who volunteer. PK testing measures the amount of a drug in the body at different time points.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EZN-2208 | Experimental |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2012-08-01
- Completion
- 2013-01-01
- First posted
- 2011-02-14
- Last updated
- 2022-02-14
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01295697. Inclusion in this directory is not an endorsement.